Also found in: Medical.
CDK2Cyclin-Dependent Kinase 2
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
CDK2 inhibitors might provide the ability to target tumors driven by cyclin E1 amplification [45, 102].
miRNA: micro-RNA RISC: RNA-induced silencing complex Ago2: Argonaut 2 TRBP: Human immunodeficiency virus transactivating response RNA-binding protein IL: Interleukins RANKL: Receptor activator of nuclear factor kappa-B ligand TLR: Toll-like receptors TNF-[alpha]: Tumor necrosis factor alpha MMP: Matrix metalloproteinases CCL2: Chemokine ligand 2 CDK2: Cyclin-dependent kinase 2 Cyr61: Cysteine-rich angiogenic inducer 61 TNFAIP3: Tumor necrosis factor alpha-induced protein 3 BCL2: B cell lymphoma 2 M-CSF: Macrophage colony-stimulating factor IKK-[alpha]: Inhibitor of nuclear factor kappa-B kinase subunit alpha PADI4: Peptidylarginine deiminase 4 gene Tregs: Regulatory T cells PTPN22: Protein tyrosine phosphatase, nonreceptor type 22 gene.
Meyerson, "Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase," Nature, vol.
((b) day 5, (d) day 10) The quantitation of activated or phosphorylated ERKs for cells from 2 separate 24-year-old women and a 27-year-old woman was determined by normalization of phosphorylated ERKs to total ERKs after normalization to Cdk2 as a loading control and expressed as a percent of untreated control cells.
The following primary antibodies were used in this study: [alpha]-SMA, [alpha]1(I) procollagen, and fibronectin (Epitomics, San Francisco, CA, USA); TGF-[beta]RI, TGF-[beta]RII, PDGF-[beta]R, EGF-R, and Bcl-2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); cyclin A, cyclin B1, CDK1, CDK2, Bax, pro-caspase-9, cleaved-caspase-9, pro-caspase-8, cleaved-caspase-8, pro-caspase-7, cleaved-caspase-7, pro-caspase-3, cleaved-caspase-3, full-length PARP-1, cleaved-PARP-1, and [beta]-Actin (Cell Signaling Technology, Danvers, MA, USA).
Golsteyn, "Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: A role beyond the cell cycle," Cancer Letters, vol.
The CDK2-proteasome-XPO1 cluster was enriched with pharmacological options, including the proteasome inhibitor bortezomib, which is available clinically, and CDK2 and XPO1 inhibitors, which are under active clinical trials for various tumor types (Figure 2(c)) [29,30]: XPO1 inhibitors have been used to target platinum-resistant ovarian tumors [31] and have been described as potentially inhibiting abnormal NFkB signaling [32].
Gardner, "Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity," The Journal of Steroid Biochemistry and Molecular Biology, vol.
Ectopic expression of circ-Foxo3 can result in the formation of the circ-Foxo3-p21-CDK2 ternary complex, arising from binding circ-Foxo3 to cell cycle proteins CDK2 and p21.
Subsequently, E2F activates the transcription of CycE, which forms a complex with Cdk2 to further remove Rb repression, establishing a positive feedback loop.
p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
This effect was observed in other cancers (Xiang et al., 2011) where lovastatin inhibited cell proliferation in ATC strains aggressive thyroid cancer in vitro, raising the level of p27 protein, which inhibits the activity of CDK2 holding the cells in [G.sub.1] phase.